MBX
MBX BiosciencesDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
Current thesis
Positive clinical or regulatory outcomes plus a partnership/licensing deal would re-rate the stock; partnership proceeds and reduced dilution support the >50% upside implied by the bull target.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -0.2.
What can break
Clinical setbacks, missed guidance, or dilutive financing would likely trigger sharp declines, consistent with the >30% downside implied by the bear target.
Momentum
99
Value
46
Sentiment
10
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $37.94 · Bull $51.74 · Bear $24.14
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2025-11-29 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-21
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $69.00
Why
Momentum99 · Δ7d -0.2
Value46 · Δ7d +0.0
Sentiment10 · Δ7d -0.7
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
99
26% active weight
Current posture
7d trendFlat
Δ7d
-0.2
Δ21d
+3.0
Value
46
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
+0.0
Sentiment
10
34% active weight
Current posture
7d trendFlat
Δ7d
-0.7
Δ21d
-10.0
Why this grade
Composite grade D. Momentum 99.3 / Value 46.4 / Sentiment 10.4
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$2.86B
Beta
-
Shares Out
47.6M
P/E (TTM) · Derived
-25.2
P/S (TTM)
-
P/FCF (TTM) · Derived
-29.30
Rev YoY
-
EPS YoY
-29.4%
Gross Margin
-
Op Margin
-
Net Debt
-$373.11M
Current Ratio
30.79
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology